Table 3.
Adherence and persistence to antithrombotic therapy at 6 months and 12 months in patients with or without chronic liver disease (CLD).
| Anticoagulants |
||||||
|---|---|---|---|---|---|---|
| Apixaban |
Rivaroxaban |
Warfarin |
||||
| With CLD | Without CLD | With CLD | Without CLD | With CLD | Without CLD | |
| Adherence and persistence at 6 months | ||||||
| Patients with at least 6 months of follow-up | 118 | 8241 | 115 | 9662 | 482 | 80390 |
| Adherent (%) | 61 (51.7) | 4842 (58.8) | 64 (55.7) | 5095 (52.7) | 172 (35.7) | 27803 (34.6) |
| Persistent (%) | 94 (79.7) | 6846 (83.1) | 94 (81.7) | 7905 (81.8) | 377 (78.2) | 62316 (77.5) |
| Adherent, persistent (%) | 55 (46.6) | 4480 (54.4) | 63 (54.8) | 4721 (48.9) | 168 (34.9) | 27017 (33.6) |
| Adherent, non-persistent (%) | 6 (5.1) | 362 (4.4) | 1 (0.9) | 374 (3.9) | 4 (0.8) | 786 (1.0) |
| Non-adherent, persistent (%) | 39 (33.1) | 2366 (28.7) | 31 (27.0) | 3184 (33.0) | 209 (43.4) | 35299 (43.9) |
| Non-adherent, non-persistent (%) | 18 (15.3) | 1033 (12.5) | 20 (17.4) | 1383 (14.3) | 101 (21.0) | 17288 (21.5) |
| Adherence and persistence at 12 months | ||||||
| Patients with at least 12 months of follow-up | 103 | 7584 | 101 | 9135 | 453 | 77370 |
| Adherent (%) | 44 (42.7) | 3544 (46.7) | 52 (51.5) | 3828 (41.9) | 125 (27.6) | 20302 (26.2) |
| Persistent (%) | 69 (67.0) | 5334 (70.3) | 75 (74.3) | 6217 (68.1) | 295 (65.1) | 49687 (64.2) |
| Adherent, persistent (%) | 39 (37.9) | 3147 (41.5) | 50 (49.5) | 3351 (36.7) | 122 (26.9) | 19693 (25.5) |
| Adherent, non-persistent (%) | 5 (4.9) | 397 (5.2) | 2 (2.0) | 477 (5.2) | 3 (0.7) | 609 (0.8) |
| Non-adherent, persistent (%) | 30 (29.1) | 2187 (28.8) | 25 (24.8) | 2866 (31.4) | 173 (38.2) | 29994 (38.8) |
| Non-adherent, non-persistent (%) | 29 (28.2) | 1853 (24.4) | 24 (23.8) | 2441 (26.7) | 155 (34.2) | 27074 (35.0) |
| Antiplatelets |
||||||
| Aspirin |
Clopidogrel |
Dipyridamole |
||||
| With CLD | Without CLD | With CLD | Without CLD | With CLD | Without CLD | |
| Adherence and persistence at 6 months | ||||||
| Patients with at least 6 months of follow-up | 1582 | 204369 | 871 | 74338 | 111 | 18115 |
| Adherent (%) | 653 (41.3) | 70920 (34.7) | 430 (49.4) | 34768 (46.8) | 48 (43.2) | 7995 (44.1) |
| Persistent (%) | 1290 (81.5) | 156873 (76.8) | 751 (86.2) | 62182 (83.6) | 95 (85.6) | 14828 (81.9) |
| Adherent, persistent (%) | 639 (40.4) | 69812 (34.2) | 414 (47.5) | 31779 (42.7) | 47 (42.3) | 7219 (39.9) |
| Adherent, non-persistent (%) | 14 (0.9) | 1108 (0.5) | 16 (1.8) | 2989 (4.0) | 1 (0.9) | 776 (4.3) |
| Non-adherent, persistent (%) | 651 (41.2) | 87061 (42.6) | 337 (38.7) | 30403 (40.9) | 48 (43.2) | 7609 (42.0) |
| Non-adherent, non-persistent (%) | 278 (17.6) | 46388 (22.7) | 104 (11.9) | 9167 (12.3) | 15 (13.5) | 2511 (13.9) |
| Adherence and persistence at 12 months | ||||||
| Patients with at least 12 months of follow-up | 1482 | 197656 | 810 | 72016 | 103 | 17681 |
| Adherent (%) | 540 (36.4) | 62276 (31.5) | 340 (42.0) | 27870 (38.7) | 32 (31.1) | 6585 (37.2) |
| Persistent (%) | 1018 (68.7) | 131953 (66.8) | 593 (73.2) | 53298 (74.0) | 77 (74.8) | 12904 (73.0) |
| Adherent, persistent (%) | 526 (35.5) | 60909 (30.8) | 315 (38.9) | 24547 (34.1) | 28 (27.2) | 5753 (32.5) |
| Adherent, non-persistent (%) | 14 (0.9) | 1367 (0.7) | 25 (3.1) | 3323 (4.6) | 4 (3.9) | 832 (4.7) |
| Non-adherent, persistent (%) | 492 (33.2) | 71044 (35.9) | 278 (34.3) | 28751 (39.9) | 49 (47.6) | 7151 (40.4) |
| Non-adherent, non-persistent (%) | 450 (30.4) | 64336 (32.5) | 192 (23.7) | 15395 (21.4) | 22 (21.4) | 3945 (22.3) |